Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Phase I of Brilife Trial Comes to a Close

Phase I of Brilife Trial Comes
Trial of the COVID-19 vaccine developed by the Israel Institute of Biological Research is set to move into Phase II within a few weeks. It will be administered in hospitals across Israel. At the same time, Putin verifies Russia is considering manufacturing its vaccine in Israel.

Sheba Medical Center and Hadassah-University Medical Center inoculated 80 volunteers with Brilife, Israel’s coronavirus vaccine, thereby completing the Phase I clinical trial. The vaccine was developed by the Israeli Institute of Biological Research, and about 40 healthy volunteers between the ages of 18 to 55 received it at each of the two hospitals.

So far, all of the volunteers are feeling well. They have been monitored closely for any adverse side effects, and follow-up checks will continue.

The Phase II trial of Brilife is due to begin in hospitals across Israel within the next three weeks. During this stage, older adults and some people with preexisting medical conditions will be vaccinated.

At the same time, Russian President Vladimir Putin verified that his country is discussing the Israeli manufacture and distribution of its COVID-19 vaccine, Sputnik V. At an inauguration ceremony for new ambassadors in Moscow last week, Putin spoke about Russia’s vaccine candidate, which was recently reported to have a 91.4% efficacy rate (based on its Phase III trial results). Putin remarked on the importance of an Israeli-Russian collaboration in the fight against coronavirus, “including the possibility of supplying and producing a Russian vaccine on Israeli soil.”

The ceremony was attended by Israeli Ambassador to Moscow, Alexander Ben Zvi, and Putin also expressed how relations with Israel are “good and beneficial,” and that he is in regular contact with Prime Minister Benjamin Netanyahu.

The Moscow branch of Hadassah University Medical Center has been participating in the Phase III trial of Sputnik V, and the option of manufacturing the vaccine in Israel is stated in the memorandum of understanding signed between both countries. At the same time, Rotstein is striving for Israel’s participation in the Phase III study (not just in Moscow), and to get the National Health Ministry’s authorization for Sputnik V to be used in Israel. His plans are to facilitate the purchase of 1.5 million doses of the vaccine, with an option to double that number to 3 million.

Sheba DUNS 100

For The Second Consecutive Year: Sheba Tops the Healthcare Sector on Dun & Bradstreet’s List of Leading Organizations

Dun & Bradstreet, the world’s foremost commercial data company, ranked 71 doctors from Sheba Medical Center in its list of the top Israeli clinical experts.…
Read More

Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More